Raymond James Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $83
Raymond James analyst Jayson Bedford maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from $85 to $83.
Mizuho Maintains Buy on Edwards Lifesciences, Lowers Price Target to $85
Mizuho analyst Anthony Petrone maintains Edwards Lifesciences (NYSE:EW) with a Buy and lowers the price target from $100 to $85.
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
Morgan Stanley raised JPMorgan Chase & Co. (NYSE:JPM) price target from $126 to $153. . Morgan Stanley analyst…
Stifel Downgrades Edwards Lifesciences to Hold, Lowers Price Target to $75
Stifel analyst Rick Wise downgrades Edwards Lifesciences (NYSE:EW) from Buy to Hold and lowers the price target from $95 to $75.
Wolfe Research Downgrades Edwards Lifesciences to Peer Perform
Wolfe Research analyst Mike Polark downgrades Edwards Lifesciences (NYSE:EW) from Outperform to Peer Perform.
Reata Pharmaceuticals To Jump 220%? Plus JP Morgan Predicts $51 For Las Vegas Sands
Goldman Sachs boosted the price target on Reata Pharmaceuticals, Inc. (NASDAQ: RETA) from $86 to $115. Goldman Sachs analyst Madhu Kumar maintained the stock with a Buy rating. Reata Pharmaceuticals shares rose 1.9% to close at $36.03 on Friday.
RBC Capital Maintains Outperform on Edwards Lifesciences, Lowers Price Target to $105
RBC Capital analyst Shagun Singh maintains Edwards Lifesciences (NYSE:EW) with a Outperform and lowers the price target from $118 to $105.
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's session saw 184 companies set new 52-week lows.
Goldman Sachs Maintains Neutral on Edwards Lifesciences, Lowers Price Target to $73
Goldman Sachs analyst Amit Hazan maintains Edwards Lifesciences (NYSE:EW) with a Neutral and lowers the price target from $97 to $73.
Cramer’s Take On This Stock That’s Down 53% Year-To-Date: ‘I Think Long-Term. I Don’t Want To Own It’
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Cerence Inc. (NASDAQ: CRNC) can fall to $13, $12 in a market like this. "If you can take that level of pain, you can absolutely buy it, because it is a good company," he added.